FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology (Q43862557)

27 November 2017

title

FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology (English)

1 reference

non-small-cell lung carcinoma

27 November 2017

0 references

1 reference

Fluorodeoxyglucose Positron Emission Tomography

inferred from title

1 reference

Jin Sook Ryu

1

1 reference

27 November 2017

Noah C Choi

2

1 reference

27 November 2017

Alan J Fischman

3

1 reference

27 November 2017

Thomas J Lynch

4

1 reference

27 November 2017

Douglas J Mathisen

5

1 reference

27 November 2017

publication date

1 February 2002

1 reference

27 November 2017

1 reference

27 November 2017

volume

35

1 reference

27 November 2017

issue

2

1 reference

27 November 2017

page(s)

179-187

1 reference

Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900332-4

7 January 2021

A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900332-4

7 January 2021

Neoadjuvant therapy: a novel and effective treatment for stage IIIb non-small cell lung cancer. Southwest Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900332-4

7 January 2021

Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small-cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900332-4

7 January 2021

CT and MR imaging in staging non-small cell bronchogenic carcinoma: report of the Radiologic Diagnostic Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900332-4

7 January 2021

Assessment of preoperative accelerated radiotherapy and chemotherapy in stage IIIA (N2) non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900332-4

7 January 2021

Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900332-4

7 January 2021

Staging non-small cell lung cancer by whole-body positron emission tomographic imaging

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900332-4

7 January 2021

Positron emission tomography in the pretreatment evaluation and follow-up of non-small cell lung cancer patients treated with radiotherapy: preliminary findings

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900332-4

7 January 2021

Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900332-4

7 January 2021

Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900332-4

7 January 2021

Performance characteristics of an eight-ring whole body PET scanner

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900332-4

7 January 2021

Regional lymph node classification for lung cancer staging

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900332-4

7 January 2021

Overview by an oncologist: what are the imaging needs of the oncologist and oncological surgeon?

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900332-4

7 January 2021

Clinical assessment of therapeutic effects on cancer using 18F-2-fluoro-2-deoxy-D-glucose and positron emission tomography: preliminary study of lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900332-4

7 January 2021

The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900332-4

7 January 2021

Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900332-4

7 January 2021

Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900332-4

7 January 2021

10.1016/S0169-5002(01)00332-4

Identifiers

DOI

1 reference

27 November 2017

1 reference